PLAT and Stroke: That incidence is comparable to the 3.7% sICH rate reported in a recent meta-analysis of 3391 rt-PA-treated strokes from nine randomized trials and lower than the rate of NINDS-tPA (6.4%), which played a pivotal role in the FDA approval of r-tPA [37].